
Ajooni Biotech (AJOONI) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
292.7M
Gross Profit
65.7M
22.46%
Operating Income
6.3M
2.16%
Net Income
15.4M
5.27%
Balance Sheet Metrics
Total Assets
950.5M
Total Liabilities
69.7M
Shareholders Equity
880.8M
Debt to Equity
0.08
Cash Flow Metrics
Revenue & Profitability Trend
Ajooni Biotech Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.1B | 801.1M | 744.9M | 740.4M | 510.4M |
Cost of Goods Sold | 970.3M | 703.5M | 657.4M | 640.1M | 430.1M |
Gross Profit | 176.6M | 97.6M | 87.4M | 100.2M | 80.3M |
Gross Margin % | 15.4% | 12.2% | 11.7% | 13.5% | 15.7% |
Operating Expenses | |||||
Research & Development | - | 670.0K | 2.4M | 498.0K | 699.0K |
Selling, General & Administrative | - | 32.4M | 20.5M | 28.8M | 32.0M |
Other Operating Expenses | 112.2M | 18.4M | 13.4M | 19.0M | 15.9M |
Total Operating Expenses | 112.2M | 51.4M | 36.3M | 48.3M | 48.6M |
Operating Income | 25.9M | 15.1M | 17.6M | 22.2M | 12.1M |
Operating Margin % | 2.3% | 1.9% | 2.4% | 3.0% | 2.4% |
Non-Operating Items | |||||
Interest Income | - | 5.0M | 2.0M | 6.0K | 2.1K |
Interest Expense | 3.3M | 5.5M | 4.7M | 5.4M | 4.9M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 43.3M | 30.0M | 15.8M | 14.6M | 5.0M |
Income Tax | 9.6M | 8.3M | 4.5M | 4.1M | 1.3M |
Effective Tax Rate % | 22.1% | 27.9% | 28.7% | 28.2% | 26.0% |
Net Income | 33.7M | 21.6M | 11.2M | 10.5M | 3.7M |
Net Margin % | 2.9% | 2.7% | 1.5% | 1.4% | 0.7% |
Key Metrics | |||||
EBITDA | 57.6M | 31.1M | 30.5M | 32.3M | 15.8M |
EPS (Basic) | - | - | ₹1.51 | ₹0.16 | ₹0.06 |
EPS (Diluted) | - | - | ₹1.51 | ₹0.16 | ₹0.06 |
Basic Shares Outstanding | - | - | 7460613 | 64999850 | 64348577 |
Diluted Shares Outstanding | - | - | 7460613 | 64999850 | 64348577 |
Income Statement Trend
Ajooni Biotech Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 68.3M | 4.3M | 3.1M | 574.0K | 2.4M |
Short-term Investments | 2.7M | 22.0K | 5.1M | 1.2M | 1.6M |
Accounts Receivable | 162.2M | 129.6M | 205.5M | 138.4M | 137.1M |
Inventory | 239.9M | 153.7M | 69.9M | 58.8M | 53.8M |
Other Current Assets | 13.9M | - | 25.4M | 18.6K | 1.1M |
Total Current Assets | 620.0M | 323.3M | 346.7M | 219.3M | 214.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 109.3M | 0 | 62.9M | 62.1M | 51.6M |
Goodwill | 4.8M | 0 | 0 | 0 | 0 |
Intangible Assets | 4.8M | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 24.0M | - | 15.0M | - | 1.4M |
Total Non-Current Assets | 330.5M | 151.9M | 240.6M | 70.9M | 66.0M |
Total Assets | 950.5M | 475.2M | 587.3M | 290.2M | 280.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 35.0M | 15.8M | 101.1M | 68.0M | 54.0M |
Short-term Debt | 0 | 4.9M | 34.3M | 27.7M | 48.9M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.9M | - | 10.4M | 380.0K | 412.0K |
Total Current Liabilities | 48.2M | 30.1M | 152.1M | 100.6M | 104.8M |
Non-Current Liabilities | |||||
Long-term Debt | 19.4M | 16.8M | 17.5M | 25.8M | 19.0M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | - | -5.0K | -1.0K | -1.0K | 301.0K |
Total Non-Current Liabilities | 21.5M | 18.0M | 18.5M | 25.8M | 19.3M |
Total Liabilities | 69.7M | 48.1M | 170.6M | 126.4M | 124.1M |
Equity | |||||
Common Stock | 344.5M | 175.2M | 175.2M | 100.1M | 100.1M |
Retained Earnings | - | - | - | - | - |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 880.8M | 427.1M | 416.7M | 163.8M | 156.2M |
Key Metrics | |||||
Total Debt | 19.4M | 21.7M | 51.8M | 53.5M | 67.8M |
Working Capital | 571.8M | 293.2M | 194.6M | 118.7M | 109.5M |
Balance Sheet Composition
Ajooni Biotech Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 43.3M | 30.0M | 15.8M | 14.6M | 5.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -236.4M | 11.9M | -114.1M | -6.8M | -38.3M |
Operating Cash Flow | -198.6M | 42.4M | -95.5M | 14.6M | -27.4M |
Investing Activities | |||||
Capital Expenditures | -10.8M | -55.7M | -28.6M | 991.0K | -35.3M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -169.5M | - | -131.7M | 0 | - |
Investment Sales | - | 127.0M | - | 1.3M | - |
Investing Cash Flow | -180.2M | 71.4M | -160.3M | 2.3M | -34.1M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 249.0M | -29.4M | 377.5M | -21.1M | 23.9M |
Free Cash Flow | -197.7M | -95.5M | -84.4M | 15.6M | -23.7M |
Net Change in Cash | -129.8M | 84.3M | 121.7M | -4.3M | -37.6M |
Cash Flow Trend
Ajooni Biotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.05
Price to Book
2.29
Price to Sales
0.43
Profitability Ratios
Profit Margin
3.06%
Operating Margin
1.49%
Return on Equity
4.23%
Return on Assets
1.50%
Financial Health
Current Ratio
13.92
Debt to Equity
6.04
Beta
0.33
Per Share Data
EPS (TTM)
₹0.20
Book Value per Share
₹2.27
Revenue per Share
₹5.29
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
ajooni | 518.6M | 26.05 | 2.29 | 4.23% | 3.06% | 6.04 |
Nestle India | 2.3T | 75.20 | 58.11 | 79.99% | 15.21% | 29.11 |
Britannia Industries | 1.5T | 66.67 | 33.60 | 49.73% | 12.02% | 28.45 |
Gokul Agro Resources | 49.4B | 18.49 | 4.72 | 23.71% | 1.31% | 52.50 |
Gujarat Ambuja | 48.6B | 20.37 | 1.60 | 8.30% | 4.94% | 7.62 |
Gopal Snacks | 45.9B | 237.52 | 11.16 | 4.69% | -0.19% | 16.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.